|
|
Vaccine Detail
|
Genetically Engineered Allogeneic Prostate Carinoma Cells Secreting Interleukin-2 and Interferon Gamma |
| Vaccine Information |
- Vaccine Name: Genetically Engineered Allogeneic Prostate Carinoma Cells Secreting Interleukin-2 and Interferon Gamma
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: interleukin-2 and interferon gamma (NCT00002637)
- Immunization Route: Other
- Description: HLA class I-matched allogeneic human prostate carcinoma cells are genetically engineered to secrete interleukin-2 and interferon gamma for patients with prostate carcinoma. Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells. Combining interferon gamma with interleukin-2 may be a more effective treatment for prostate cancer. (NCT00002637)
|
| Host Response |
|
|
| References |
NCT00002637: Biological Therapy in Treating Patients With Prostate Cancer [https://clinicaltrials.gov/study/NCT00002637]
|
|
